Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

994
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
994
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

601
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
601
Transducer Mechanism: G Protein–Coupled Receptors01:30

Transducer Mechanism: G Protein–Coupled Receptors

6.7K
G Protein–Coupled Receptors (GPCRs) are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to various stimuli. GPCRs regulate critical physiological pathways and are excellent drug targets for treating diseases such as diabetes, cancer, obesity, depression, or Alzheimer's. Nearly 35% of approved drugs implement their therapeutic effects by selectively interacting with specific GPCRs.
GPCRs are also called heptahelical,...
6.7K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

61
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
61
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

8.0K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
8.0K
Carrier-Mediated Transport01:06

Carrier-Mediated Transport

1.5K
Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A critical analysis on ENaC inhibitors, unravelling molecular medicinal insights and promising research roadmap in the treatment of cystic fibrosis.

European journal of medicinal chemistry·2026
Same author

Functional correction of the untreatable <i>CFTR</i> 1717-1G>A mutation through mRNA- and sgRNA-optimized base editing.

Science translational medicine·2026
Same author

Evaluation of ATP12A and NFKBIZ as potential markers of inflammatory status in cystic fibrosis airway epithelial cells.

Inflammation research : official journal of the European Histamine Research Society ... [et al.]·2026
Same author

Rescue of the CFTR chloride channel with nonsense mutations is markedly improved under inflammatory conditions.

The European respiratory journal·2025
Same author

Modulators of anion channels and transporters as alternative therapeutic agents to normalize airway surface liquid in cystic fibrosis.

European journal of medicinal chemistry·2025
Same author

In silico, in vitro and ex vivo characterization of cystic fibrosis transmembrane conductance regulator pathogenic variants localized in the fourth intracellular loop and their rescue by modulators.

British journal of pharmacology·2025

Related Experiment Video

Updated: Mar 14, 2026

Purification of the Cystic Fibrosis Transmembrane Conductance Regulator Protein Expressed in Saccharomyces cerevisiae
15:12

Purification of the Cystic Fibrosis Transmembrane Conductance Regulator Protein Expressed in Saccharomyces cerevisiae

Published on: May 10, 2014

15.1K

CFTR pharmacology.

Olga Zegarra-Moran1, Luis J V Galietta2

  • 1U.O.C. Genetica Medica, Istituto Giannina Gaslini, Via Gerolamo Gaslini 5, 16147, Genoa, Italy.

Cellular and Molecular Life Sciences : CMLS
|October 6, 2016
PubMed
Summary

Pharmacological modulators targeting the cystic fibrosis transmembrane conductance regulator (CFTR) protein show promise for treating various diseases. These CFTR drugs, including correctors and potentiators, offer potential therapeutic benefits for conditions like cystic fibrosis and COPD.

Keywords:
CFTRChannel blockerChloride channelCystic fibrosis

More Related Videos

Functional Reconstitution and Channel Activity Measurements of Purified Wildtype and Mutant CFTR Protein
09:59

Functional Reconstitution and Channel Activity Measurements of Purified Wildtype and Mutant CFTR Protein

Published on: March 9, 2015

12.8K
Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients
07:04

Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients

Published on: February 11, 2017

20.2K

Related Experiment Videos

Last Updated: Mar 14, 2026

Purification of the Cystic Fibrosis Transmembrane Conductance Regulator Protein Expressed in Saccharomyces cerevisiae
15:12

Purification of the Cystic Fibrosis Transmembrane Conductance Regulator Protein Expressed in Saccharomyces cerevisiae

Published on: May 10, 2014

15.1K
Functional Reconstitution and Channel Activity Measurements of Purified Wildtype and Mutant CFTR Protein
09:59

Functional Reconstitution and Channel Activity Measurements of Purified Wildtype and Mutant CFTR Protein

Published on: March 9, 2015

12.8K
Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients
07:04

Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients

Published on: February 11, 2017

20.2K

Area of Science:

  • Biochemistry and Molecular Biology
  • Physiology
  • Pharmacology

Background:

  • The cystic fibrosis transmembrane conductance regulator (CFTR) protein functions as a crucial ion channel in epithelial cells.
  • CFTR regulates chloride and bicarbonate transport, vital for respiratory and gastrointestinal functions.

Purpose of the Study:

  • To explore the therapeutic potential of pharmacological CFTR modulators.
  • To investigate the application of CFTR correctors and potentiators for cystic fibrosis.
  • To assess the utility of CFTR potentiators in chronic obstructive pulmonary disease (COPD) and CFTR inhibitors for secretory diarrhea and polycystic kidney disease.

Main Methods:

  • Investigated the role of cAMP-dependent phosphorylation in CFTR regulation.
  • Reviewed the mechanisms of action for CFTR correctors, potentiators, and inhibitors.
  • Examined the therapeutic applications of CFTR modulators in various disease models.

Main Results:

  • CFTR correctors and potentiators demonstrate potential to restore CFTR function in cystic fibrosis.
  • CFTR potentiators may enhance mucociliary clearance in COPD patients.
  • CFTR inhibitors show promise in managing fluid loss in secretory diarrhea and slowing polycystic kidney disease progression.

Conclusions:

  • Pharmacological modulation of CFTR represents a promising therapeutic strategy for multiple diseases.
  • Targeting CFTR offers distinct benefits for conditions ranging from genetic disorders to chronic inflammatory diseases.